Background: A potential link between breast implants and anaplastic large-cell lymphoma (ALCL) has been suggested.
Introduction
A potential link between breast implants and anaplastic large-cell lymphoma (ALCL) of the breast has been suggested on the basis of several case reports (1) , and a Dutch case-control study reported an OR of 18.2 for ALCL among women with silicone breast implants (2) .
On the basis of the data from Danish population-based registries and private clinics, we evaluated the occurrence of ALCL and other lymphomas in a large cohort of Danish women who underwent breast implantation.
Materials and Methods

Study population
We established a nationwide cohort of Danish women who underwent breast implantation for cosmetic or reconstructive purposes during 1973-2010 (Fig. 1) . The women were identified from the Danish National Registry of Patients, which contains data on all admissions to public hospitals since 1978 (3); The Danish Registry for Plastic Surgery of the Breast, which contains detailed information on 70% to 80% of all cosmetic or reconstructive breast implant procedures carried out during 1999-2009 (4), and a previously established cohort of 1,653 women who underwent breast implantation in private clinics during 1973-1995 (5) . The vast majority of the breast implants were silicone-gel filled (4, 5) .
Study subjects were followed for a lymphoma diagnosis from the date of first breast implant surgery (left-censored to 1978) until death, emigration, or end of study (December 31, 2010). Lymphoma diagnoses were ascertained from the Danish Cancer Registry and The Danish Lymphoma Group Registry (4, 5) . Cancer diagnoses from 1978 onward are registered according to the International Classification of Diseases, version 10 (ICD-10) and the ICD for Oncology (ICD-O-1-3) for topography and morphology codes (6), thus, explaining the choice of 1978 as start of follow-up. A morphologic code for ALCL (ICD-O-3, 97143) was introduced in 1994 based on the Revised European-American Lymphoma Classification.
All cases of lymphoma following breast implant surgery were reviewed by an expert hematopathologist (coauthor K. Bendix) using World Health Organization 2008 criteria.
All data sources were linked using the civil registration number, which encodes gender and date of birth and permits unambiguous linkage between registries and databases in Denmark.
Statistical analyses
We computed standardized incidence ratios (SIR), and 95% confidence intervals (CI), for ALCL and lymphoma overall. For ALCL, the SIR analysis was left truncated to 1994 in accordance with the introduction of the specific histologic code for ALCL. For lymphoma overall, the complete study period (1978-2010) was applied. The expected numbers were estimated by multiplying the number of person-years among cohort members with the corresponding 5-year age-and calendar period-specific incidence rates among women in the general population.
Results
The study population consisted of 19,885 women. Left truncation to 1978 reduced the cohort to 19,639 women. During 1978-2010, we identified 31 cases ( Fig. 1 and Table  1 ) of Hodgkin or non-Hodgkin lymphoma versus 26.6 expected, yielding a SIR for lymphoma overall of 1.20 (95% CI, 0.82-1.70). No cases of ALCL were identified, with 0.36 expected, yielding a SIR of 0 (95% CI, 0-10.3).
Discussion
In this nationwide cohort study, we found no cases of ALCL among Danish women who underwent breast implant surgery. Our cohort approach based on virtually complete data basically eliminated selection and information bias. Furthermore, the pathologic review precluded misclassification of ALCL. Still, although our cohort was large, the risk estimate for ALCL suffered from limited statistical precision because of the rarity of the disease.
Previous epidemiologic studies (7) did not indicate an increased risk of non-Hodgkin lymphoma associated with silicone breast implants (7, 8) . An important contribution of our study has been to supplement these results with information on lymphoma subtype.
The Dutch study reporting a strong association between silicone breast implants and ALCL had some important limitations (2) . First, for 3 of 5 cases of ALCL observed among women with breast implants, the latency period was short, for example, 1 patient developed ALCL within 1 year after implantation, a time frame most likely too short to induce malignant transformation. Second, whereas all cases (n ¼ 11) in the study had ALCL of the breast, all controls (n ¼ 35) had breast lymphomas other than ALCL, thus hampering identification of the underlying study base. Third, 3 patients had disseminated disease, questioning that they were primary breast lymphomas. Finally, all 3 women with ALCL and breast implants had saline-filled implants. In our opinion, no valid conclusion can be drawn from the Dutch study with regard to a potential excess risk of ALCL among women with silicone breast implants.
In conclusion, in this first study addressing the suggested association between silicone breast implants and ALCL in a well-defined study population, we found no evidence of an association between breast implantation and risk of ALCL or lymphoma overall. On the basis of the available evidence, it seems reasonable to conclude that a potential association between silicone breast implants and ALCL is not a major safety issue. Because of the rarity of ALCL, a small to moderate excess risk is difficult to show. Therefore, additional studies with even larger sample 
